Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612948 · ClinicalTrials.gov registry record · Phase 4
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
A Phase 4 study, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
NCT02612948: Completed Phase 4 study, sponsored by University of Tennessee Graduate School of Medicine.
NCT02612948 is a Phase 4 study that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 82 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612948, a Phase 4 study, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
Study Summary
Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.
Primary Outcome
ICU length of stay
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
What the finished NCT02612948 record still lists
NCT02612948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT02612948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02612948 about?
NCT02612948 is a clinical study titled "Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients". Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.
What is the current status of trial NCT02612948?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2013-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02612948?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT02612948?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02612948's enrollment target sits among peer trials
82 939th of 2000 higher than 1,061 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia